NEW YORK — Tracer Biotechnologies has announced a strategic partnership with QIAGEN to co-develop and commercialize blood-based minimal residual disease (MRD) tests for solid tumors using QIAGEN’s QIAcuity digital PCR platform. The collaboration aims to provide oncologists with highly sensitive, cost-effective tools for monitoring cancer recurrence and guiding personalized treatment plans through non-invasive blood tests.
The partnership brings together Tracer’s expertise in molecular diagnostics with QIAGEN’s advanced digital PCR technology to create scalable MRD assays that can be seamlessly integrated into clinical workflows. These assays are designed to detect traces of cancer that may remain in the body after treatment, helping physicians tailor follow-up care and improve outcomes.
“Partnering with QIAGEN enables us to expand the reach of our MRD technologies and deliver high-performance diagnostics to more patients and healthcare providers,” said Mark Kaganovich, CEO of Tracer Biotechnologies. “The QIAcuity platform’s precision and scalability are critical to our goal of providing actionable insights in a decentralized, cost-effective manner.”
Tracer currently offers two MRD solutions: Tracer dPCR, a tumor-informed multiplexed assay for in-house use on digital PCR systems, and Tracer WGS, an AI-powered whole-genome circulating tumor DNA platform that identifies and tracks cancer without requiring prior tissue samples.
The partnership also advances QIAGEN’s role in the oncology diagnostics space. “This collaboration strengthens our ability to support personalized cancer care through innovative MRD technologies,” said Jonathan Arnold, Vice President and Head of Partnering for Precision Diagnostics at QIAGEN. “With Tracer’s expertise and QIAcuity’s robust capabilities, we are providing pharmaceutical partners and clinicians with powerful tools for improving treatment decisions.”
Both companies aim to accelerate adoption of MRD testing in routine cancer care and drug development, emphasizing accessibility, speed, and precision.
